In an asymptomatic, euthyroid patient with a 0.9 cm thyroid nodule on ultrasound, which factor indicates the need for further investigation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

D. Features of malignancy

For a 0.9 cm thyroid nodule in an asymptomatic, euthyroid patient, the presence of suspicious ultrasound features of malignancy is the primary indication for further investigation (fine needle aspiration biopsy). 1

Rationale Based on Guidelines

The ACR TI-RADS guidelines (2017) establish that size alone does not determine biopsy indication—rather, the combination of size AND ultrasound risk stratification drives management 1. For a 0.9 cm nodule:

  • High-suspicion nodules (TR5): Biopsy recommended at ≥1 cm 1
  • Moderately suspicious nodules (TR4): Biopsy recommended at ≥1.5 cm 1
  • Mildly suspicious nodules (TR3): Biopsy recommended at ≥2.5 cm 1

Since this nodule is 0.9 cm, it falls below the 1 cm threshold for high-suspicion features. However, if ultrasound demonstrates high-risk features (microcalcifications, irregular margins, taller-than-wide shape, marked hypoechogenicity), this would classify it as potentially requiring biopsy once it reaches 1 cm, or at minimum, close surveillance 1.

Why Other Options Are Incorrect

Age (Option A): While age >39 years correlates with increased malignancy risk 2, age alone does not indicate the need for investigation in a subcentimeter nodule. The 2024 guideline on thyroid biopsy appropriateness emphasizes that ultrasound findings remain the primary driver, with risk factors like age serving as modifying factors only when ultrasound findings are equivocal 3.

History of radiation exposure (Option B): Radiation history is a risk factor for thyroid cancer but does not independently mandate investigation of a 0.9 cm nodule without suspicious ultrasound features 3.

Size of tumor (Option C): At 0.9 cm, this nodule is below standard biopsy thresholds even for high-suspicion lesions 1. The ACR TI-RADS specifically recommends against biopsying nodules <1 cm to avoid overdiagnosis of indolent cancers 1. Recent evidence confirms that subcentimeter nodules without suspicious features have negligible clinical significance 4.

Family history of thyroiditis (Option E): Family history of benign thyroid disease (thyroiditis) does not increase malignancy risk and is not an indication for investigation. Family history of thyroid cancer would be relevant, but that's not what this option states.

Key Ultrasound Features That Drive Investigation

The most predictive malignant features include 5, 6, 7:

  • Microcalcifications (specificity 72-86%)
  • Irregular or lobulated margins (specificity 66-89%)
  • Taller-than-wide shape (specificity 79-92%)
  • Marked hypoechogenicity (specificity 75%)
  • Solid composition with posterior acoustic shadowing

A nodule showing ANY of these features warrants heightened surveillance and consideration for biopsy once it reaches appropriate size thresholds 6.

Clinical Pitfalls to Avoid

  1. Don't biopsy based on size alone: A 0.9 cm nodule with benign ultrasound features (U2 classification) requires no further action 1, 8

  2. Don't order thyroid US in euthyroid patients without palpable abnormalities: This leads to overdiagnosis 4

  3. Don't ignore high-risk ultrasound features: Even if below size threshold, these nodules need structured surveillance with repeat US in 12 months 1

  4. Recognize that patient anxiety is not an indication for biopsy: The 2024 appropriateness criteria emphasize that biopsies unlikely to change management cause more harm than benefit 3

Recommended Management Algorithm

For this 0.9 cm nodule:

  1. Perform risk stratification using ACR TI-RADS or equivalent U-score system 1
  2. If high-suspicion features present: Repeat US at 12 months; biopsy if growth to ≥1 cm 1
  3. If moderate-suspicion features: Repeat US at 12-24 months; biopsy only if reaches ≥1.5 cm 1
  4. If low-suspicion features: No biopsy indicated regardless of size up to 2.5 cm 1

1, 5, 6, 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.